NEXT HORIZON / 5 NEWS OF THE DAY / 22 NOVEMBER 2026
A New Orbit at Mercury, a Cancer Trial, and the Machines That Help Us See More
A spacecraft is approaching a new chapter at Mercury, while a small pancreatic cancer trial is offering a promising but still incomplete picture of a treatment combination.
In a chemistry laboratory, wireless sensors are turning reaction vessels into sources of continuous data; far beyond the planets, Voyager 1 has crossed a remarkable distance milestone even as engineers investigate a communications problem.
Our fifth story revisits an earlier Stanford study of brain activity and Alzheimer’s risk, because its central question is still worth examining: how early can a statistical warning become clinically useful?
Not all five developments were first published in the past day, and the original dates are stated plainly below.
What connects them is the difference between a compelling measurement and the much harder task of knowing exactly what it proves.
![]() |
| Five stories on Mercury exploration, pancreatic cancer treatment research, wireless chemistry, Voyager 1, and brain-based risk prediction. Conceptual illustrations. |
BepiColombo Reaches Its Mercury Orbit-Insertion Date — But Confirmation Matters
21 November 2026 event; ESA mission plan published earlier
Mercury is a difficult place to reach. A spacecraft travelling toward the Sun gains speed as it falls deeper into the Sun’s gravitational field, so arriving near the planet is not the same thing as slowing down enough to remain there. That is why the European Space Agency and Japan’s space agency designed BepiColombo as a long journey involving carefully planned flybys, trajectory corrections and a final orbit-insertion sequence. ESA’s published mission timeline places the crucial insertion on 21 November 2026, following the separation of its Mercury Transfer Module on 3 September.
BepiColombo carries two science orbiters: ESA’s Mercury Planetary Orbiter, or MPO, and JAXA’s Mercury Magnetospheric Orbiter, Mio. At this stage the orbiters remain joined. Their separation is planned for 9–10 December, and the main science phase is expected to begin in April 2027. This is an important distinction: reaching the planned insertion date does not mean the two probes have already begun their normal science campaigns. Nor does a schedule, on its own, constitute independent confirmation that every manoeuvre succeeded.
The mission’s scientific value lies in the complementary views of Mercury that the two spacecraft can provide. MPO is designed to investigate the planet itself, including its surface, interior and magnetic field. Mio concentrates on the surrounding magnetic environment and its interaction with charged particles from the Sun. Mercury has a global magnetic field despite being small and heavily heated by the nearby Sun. Understanding how that field arises, and how it interacts with the solar wind, is a useful test of theories about planetary interiors and magnetic dynamos.
A spacecraft approaching Mercury also operates in an unusually demanding thermal environment. Solar radiation is intense, while sunlight reflected from the planet and heat emitted by its surface add to the engineering challenge. Mission planners must protect instruments and spacecraft systems while executing precise changes in velocity. The orbit-insertion campaign is therefore not a single dramatic moment so much as a carefully staged sequence of navigation and operations.
The editorial caution here is straightforward. ESA’s mission pages establish the scheduled 21 November milestone, but the sources checked for this edition did not provide a fresh, explicit post-manoeuvre confirmation. We therefore describe a planned insertion, not an independently verified success. For me, that makes the story more interesting rather than less: deep-space exploration is a discipline in which even reaching the right place at the right time is the result of years of physics, engineering and patience. The next decisive evidence will come from mission telemetry and the agency’s subsequent operational updates.
Primary source: https://www.esa.int/articles/about-us/directorates/science/bepicolombo/latest-updates-bepicolombo-s-arrival-at-mercury
A Pancreatic Cancer Combination Shows Encouraging Responses, Not Yet a Proven Survival Benefit
20 November 2026 updated conference presentation; data cutoff 28 September 2026
An updated early-stage clinical trial has reported encouraging tumour responses in people receiving daraxonrasib alongside standard chemotherapy for previously untreated metastatic pancreatic cancer. The results were presented on 20 November 2026 at the EORTC–NCI–AACR symposium in Barcelona. The study included 61 patients treated with the investigational combination in the relevant cohort, with a median follow-up of 18.3 months and a data cutoff of 28 September. The findings are significant because pancreatic cancer that has spread to other organs is exceptionally difficult to treat, but they require careful interpretation.
Daraxonrasib targets signalling by RAS proteins, which help cells respond to growth signals. Mutations in the KRAS gene are common drivers of pancreatic cancer, allowing malignant cells to keep proliferating. The treatment studied here combined oral daraxonrasib with gemcitabine and nab-paclitaxel, two established chemotherapy drugs. Rather than replacing chemotherapy, the trial examined whether adding targeted inhibition could produce deeper or more durable responses in the first-line setting.
According to the company’s reported data, the confirmed objective response rate was 60.7 percent. That means a defined degree of tumour shrinkage was documented using trial response criteria; it does not mean that 60.7 percent of patients were cured. The complete response rate was 8.2 percent, meaning no detectable target lesions on imaging under the applicable criteria. Disease control was reported in 90.2 percent, while median progression-free survival was 12.8 months. The estimated proportion alive at twelve months was 76.6 percent. Each of these numbers measures something different, and none should be casually substituted for overall survival benefit.
The most important limitation is the study design. This phase 1/2 cohort was open-label and did not randomly assign patients to the same chemotherapy with or without daraxonrasib. Historical comparisons may look attractive, but differences in patient selection, follow-up and treatment conditions can distort them. A randomized phase 3 trial is needed to establish whether the combination actually improves outcomes over the current first-line standard. Adverse effects and tolerability also matter, especially when a targeted drug is added to chemotherapy rather than used alone.
Daraxonrasib already has a separate US approval for certain patients with metastatic pancreatic cancer after previous therapy or when intensive chemotherapy is unsuitable. That approval should not be confused with approval of this newly reported first-line combination. What interests me is how precision oncology increasingly becomes a question of sequencing and combinations rather than a search for one miraculous pill. The response data offer a reason for serious further study. They are not a promise that the disease has been defeated.
Primary source: https://revmed.gcs-web.com/node/13771/pdf
Tiny Wireless Chips Let Chemists Watch Reactions as They Happen
19 November 2026 Stanford report and Science publication
A chemistry experiment often ends with a familiar inconvenience: researchers know what went into a test tube and what came out, but they have only a partial picture of what happened between those two moments. Chemists can take samples, use specialized instruments or measure changes in temperature, yet those approaches may be slow, costly or intrusive when dozens of reactions are running at once. A Stanford-led team has demonstrated another option: tiny light-powered wireless chips that can sit inside reaction vessels and report thermal information continuously.
The system uses optical wireless integrated circuits, miniature semiconductor devices roughly 0.5 millimetres across. The chips are protected by a chemically resistant coating and receive power through light rather than a wired electrical connection. They measure temperature-related changes and send information optically to a receiver. Stanford reported readings every half-second. In an hour-long batch of 96 tubes, that sampling interval could produce approximately 7,200 readings per tube, or nearly 700,000 readings in total, instead of a single end-point result from each reaction.
Why does temperature matter? Chemical reactions absorb or release heat, and the pattern of that heat flow can reveal when a process accelerates, slows or encounters trouble. In demonstrations described by the researchers, continuous monitoring helped identify problems associated with poisoned catalysts and excessive heat generation. A catalyst is a substance that speeds a reaction without being consumed in the intended overall process, but impurities can interfere with its action. Recognizing that interference during the experiment can be more useful than discovering a failed result hours later.
This is not a tiny laboratory assistant that understands the chemistry by itself. Temperature is an indirect measurement: different chemical pathways can generate overlapping thermal patterns, and interpreting those signals requires appropriate models and controls. The device does not directly identify every molecule or automatically determine the correct reaction mechanism. Its strength is that it provides a continuous, relatively unobtrusive stream of measurements that can be combined with other analytical methods.
The team imagines adapting the same platform to other properties, such as acidity, conductivity or optical behaviour, but those possibilities should be distinguished from what was actually demonstrated. For drug discovery and materials research, the practical opportunity is to improve high-throughput experimentation, particularly when automated systems must decide which conditions to test next. To me, the surprising part is the change in perspective: instead of treating a reaction as a black box whose contents are inspected at the end, the researchers have made it something that can report its condition while it is still running.
Primary source: https://chemistry.stanford.edu/news/tiny-chips-can-analyze-chemical-reactions-inside
Voyager 1 Crosses One Light-Day While Engineers Investigate Lost Data
18 November 2026 distance milestone; NASA engineering update 18 November
On 18 November 2026, Voyager 1 reached a distance from Earth of approximately one light-day: about 25.9 billion kilometres. A light-day is a unit of distance, not a duration of the spacecraft’s flight. It is how far light, or any electromagnetic signal travelling in vacuum, moves in 24 hours. Voyager took almost half a century to reach that distance after its 1977 launch. The milestone is a striking reminder that the scale of space quickly overwhelms familiar human measures of travel.
The celebration comes with an engineering complication. NASA reported that on 14 November the mission team noticed Voyager 1 had stopped returning its normal science and engineering data. Ground antennas could still receive a carrier signal from the spacecraft, suggesting its antenna remained pointed toward Earth and its radio transmission equipment was operating. But a carrier signal is not the same as a usable stream of measurements. Engineers were investigating whether a problem in onboard data collection or formatting was responsible.
The distance itself can still be established from long-running trajectory calculations and the radio signal. NASA said the mission would use those methods to confirm the one-light-day milestone on 19 November, after the relevant signal had time to reach Earth. There is no contradiction between a spacecraft continuing along its predicted path and its instruments temporarily failing to transmit their normal data. It also does not follow that the mission has permanently ended. Similar symptoms have occurred before, including a data issue investigated in 2023.
Communication delays now shape every engineering decision. A command transmitted from Earth takes roughly 24 hours to arrive. A response takes another 24 hours to return, so even a simple command-and-check cycle can require two days, before allowing for processing or antenna scheduling. That makes troubleshooting fundamentally different from repairing equipment in a laboratory. Engineers cannot open the spacecraft, restart a component by hand or quickly run a dozen interactive tests.
Voyager 1 is already beyond the heliopause, the boundary where the solar wind gives way to the interstellar environment. It has transformed our understanding of the outer planets and remains a rare source of measurements from a region no other active spacecraft has reached so far. I find the combination of achievement and fragility particularly revealing: the impressive number is not just the distance travelled but the fact that a machine built in the 1970s can still be heard at all. Whether it resumes normal data transmission is a separate, unresolved engineering question.
Primary source: https://science.nasa.gov/blogs/voyager/2026/11/18/voyager-1-engineers-analyze-data-issue-ready-to-confirm-light-day/
Can Brain Activity Reveal Alzheimer’s Risk Before Symptoms?
4 November 2026 Science Advances study; Stanford report 5 November
A study reported by Stanford Medicine earlier this month raises a difficult question: could patterns of brain activity provide an early indication of future cognitive decline before obvious memory problems appear? The researchers developed a score based on resting-state functional MRI, which measures changes associated with blood flow while a person lies quietly in a scanner. Their approach is not a direct test for the presence of Alzheimer’s disease. It is an attempt to identify patterns of functional connectivity that appear more similar to those of unusually resilient older adults or people already diagnosed with Alzheimer’s.
The team first compared scans from 180 so-called super agers, older adults whose memory performance remains unusually strong, with scans from 110 people with Alzheimer’s disease. A machine-learning approach identified patterns that separated the two groups and generated an Alzheimer’s resilience-vulnerability connectome score, abbreviated ARC. In that initial comparison the score distinguished the groups with roughly 85 percent accuracy. That figure is not the same as an 85 percent chance of correctly predicting Alzheimer’s in any person who walks into a clinic.
Researchers then applied the scoring system to data from more than 1,300 adults aged roughly 55 to 70 who were cognitively normal when scanned. Longitudinal follow-up, varying across datasets and extending up to twelve years in some cases, suggested that participants with more Alzheimer’s-like baseline patterns tended to experience faster cognitive decline. Those with more super-ager-like patterns tended to fare better. The findings suggest that functional brain organization may contain useful information not fully captured by established biomarkers such as amyloid and tau.
There are several reasons to resist turning this into a diagnostic headline. Functional MRI signals are indirect measures of neural activity, and their interpretation can be influenced by scanner settings, vascular health, movement and data-processing choices. A predictive association does not establish that the observed network pattern causes disease. It also does not prove that changing the pattern through brain stimulation or cognitive training would prevent Alzheimer’s. Those intervention ideas remain hypotheses requiring clinical trials and independent validation.
The underlying paper appeared on 4 November and Stanford’s report on 5 November, so this is deliberately a retrospective editorial selection rather than a story from the past day. It deserves another look because early prediction is meaningful only if it becomes reliable, equitable and useful enough to guide decisions. The most important question is not whether an algorithm can assign a risk score. It is whether clinicians can use that score to improve patients’ lives without producing unnecessary anxiety or false certainty. That is a much higher standard than an impressive research metric.
Primary source: https://news.stanford.edu/stories/2026/11/brain-activity-patterns-alzheimers
Explore Topics
Explore More Topics
Go deeper with curated guides that connect our best reporting around a single subject.
Dive into our in-depth guides and discover more stories around the ideas shaping our world.

Comments
Post a Comment